誼礫控股(00076.HK)子公司與Goldpay訂立商業合作合約
格隆匯6月12日丨誼礫控股(00076.HK)宣佈,公司全資附屬公司誼礫石墨有限公司("子公司")於2025年6月12日與Goldpay已訂立商業合作合約。根據該合約,將由子公司擔任顧問方、Goldpay擔任發行方,爲一批有需求且合適的公司發行各種實用性的加密代幣。雙方將把上述業務作爲開展web3項目的主要內容。作爲顧問方的子公司將涉及的顧問工作僅限於在區塊鏈的技術問題以及實用代幣的應用場景事宜。
董事會認爲,雖然結合人工智能的業務和加密貨幣使用已是大勢所趨,然而此項目未來對本集團的貢獻尚未能確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.